Literature DB >> 9176854

Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.

S Oikawa1, A Matsunaga, T Saito, H Sato, T Seki, K Hoshi, K Hayasaka, H Kotake, H Midorikawa, A Sekikawa, S Hara, K Abe, T Toyota, H Jingami, H Nakamura, J Sasaki.   

Abstract

Lipoprotein glomerulopathy (LPG) is a novel disease characterized by proteinuria, lipoprotein thrombi in the glomeruli, and increased concentration of plasma apolipoprotein (apo) E. It is believed that a genetic disorder of apo E may be present and associated with the disease. Three patients with LPG were examined in this study. The patients' DNA sequences were analyzed, and a nucleotide G to C point mutation in exon 4 of the apo E gene was confirmed in each patient. This missense mutation denotes amino acid substitution of the proline residue for arginine residue at position 145 of apo E. This variant (apo E Sendai) may cause a marked molecular conformational change of the apo E. These findings suggest that a novel variant is etiologically related to LPG.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176854     DOI: 10.1681/ASN.V85820

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  28 in total

1.  Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy.

Authors:  Yoshiro Miyahara; Shinsuke Nishimura; Maho Watanabe; Kenji Ito; Hitoshi Nakashima; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2011-11-11       Impact factor: 2.801

2.  Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.

Authors:  Hagai Tavori; Daping Fan; Ilaria Giunzioni; Lin Zhu; MacRae F Linton; Agnes B Fogo; Sergio Fazio
Journal:  J Lipid Res       Date:  2014-09-02       Impact factor: 5.922

3.  Role of Conserved Proline Residues in Human Apolipoprotein A-IV Structure and Function.

Authors:  Xiaodi Deng; Ryan G Walker; Jamie Morris; W Sean Davidson; Thomas B Thompson
Journal:  J Biol Chem       Date:  2015-03-02       Impact factor: 5.157

4.  A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I.

Authors:  Satoshi Takasaki; Akira Matsunaga; Kensuke Joh; Takao Saito
Journal:  CEN Case Rep       Date:  2018-01-22

5.  A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes.

Authors:  Tamayo Kato; Yasuyuki Ushiogi; Hitoshi Yokoyama; Shigeo Hara; Akira Matsunaga; Eri Muso; Takao Saito
Journal:  CEN Case Rep       Date:  2019-01-30

6.  Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.

Authors:  Akira Matsunaga; Masayuki Furuyama; Taeko Hashimoto; Kentaro Toyoda; Daisuke Ogino; Kiyoshi Hayasaka
Journal:  Clin Exp Nephrol       Date:  2009-07-15       Impact factor: 2.801

Review 7.  Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.

Authors:  Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-02-26       Impact factor: 2.801

8.  Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.

Authors:  Atsunori Ishimura; Maho Watanabe; Hitoshi Nakashima; Kenji Ito; Katsuhisa Miyake; Shizue Mochizuki; Yasushi Ishigaki; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2009-05-21       Impact factor: 2.801

Review 9.  Topics in lipoprotein glomerulopathy: an overview.

Authors:  Takao Saito; Akira Matsunaga; Kenji Ito; Hitoshi Nakashima
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

Review 10.  A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.

Authors:  Efstratios Stratikos; Angeliki Chroni
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.